Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results

Michael Dickinson; Carmelo Carlo-Stella; Franck Morschhauser; Emmanuel Bachy; Paolo Corradini; Gloria Iacoboni; Cyrus Khan; Tomasz Wrobel; Fritz Offner; Marek Trneny; Shang-Ju Wu; Guillaume Cartron; Mark Hertzberg; Anna Sureda Balari; David Perez-Callejo; Linda Lundberg; James Relf; Emma Clark; Kathryn Humphrey; Martin Hutchings

$Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results$

Acte de colloque

Avec comité de lecture

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results

Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wrobel, Fritz Offner, Marek Trneny, …

2022

Résumé

Biology and Life Sciences

Medicine and Health Sciences

Indicateurs

1 Consultations de la notice

Détails

Titre: Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
Créateurs - sans rôle: Michael Dickinson
Carmelo Carlo-Stella
Franck Morschhauser
Emmanuel Bachy
Paolo Corradini
Gloria Iacoboni
Cyrus Khan
Tomasz Wrobel
Fritz Offner
Marek Trneny
Shang-Ju Wu
Guillaume Cartron
Mark Hertzberg
Anna Sureda Balari
David Perez-Callejo
Linda Lundberg
James Relf
Emma Clark
Kathryn Humphrey
Martin Hutchings
Éditeur: Lippincott Williams & Wilkins
Identifiants: 99139648909311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Conference proceeding